Aeglea BioTherapeutics Inc

-0.20 (-2.38%)
Earnings Announcements

Aeglea Biotherapeutics Reports Q4 And FY20 Financial Results And Corporate Highlights

Published: 03/18/2021 12:47 GMT
Aeglea BioTherapeutics Inc (AGLE) - Aeglea Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights.
Aeglea Bio Therapeutics Inc - Phase 3 Peace Study Enrollment Expected to Complete in March; Topline Data Expected in Q4.
Aeglea Bio Therapeutics Inc - Believes It Has Sufficient Capital Resources to Fund Anticipated Operations Into 2023.
Revenue is expected to be $4.01 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0.69 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.